FDA Asks: Does Obesity Change Your Pill Dosage? Comment Now!
Published Date: 5/1/2026
Notice
Summary
The FDA wants to hear from everyone about how obesity might change the way medicines work and how they should be dosed. This could help make sure people with obesity get the safest and most effective drug doses. If you have ideas, send your comments by June 30, 2026—this could shape future drug rules and impact healthcare costs.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA Seeks Input on Obesity and Drug Dosing
If you have obesity or care for a child with obesity, the FDA is asking for public comments by June 30, 2026 (Docket No. FDA-2026-N-3499) about how obesity changes drug effects and whether dosing recommendations should differ. The notice cites that about 40% of adults and about 20% of children have obesity and defines adult obesity as body mass index (BMI) of >=30 kg/m2 and pediatric obesity as BMI at or above the 95th percentile.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16944, Gardenia Blue Interest Group; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Gardenia Blue Interest Group (GBIG or petitioner), c/o Exponent, Inc., proposing that we amend our color additive regulations to expand the safe use of gardenia (genipin) blue in various foods at levels consistent with good manufacturing practice. The petition also proposes to lower the specification for arsenic in gardenia (genipin) blue.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16943, International Association of Color Manufacturers; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by the International Association of Color Manufacturers, proposing that we amend our color additive regulations to provide for the safe use of acetone as a solvent in the manufacture of carrot oil. The petition also proposes to add heavy metal limits and secondary names for carrot oil. FDA may also consider other changes to the regulation, as appropriate, during the course of our review.
Previous / Next Documents
Previous: 2026-08520, Environmental Impact Statements; Notice of Availability
The EPA just shared new Environmental Impact Statements (EIS) for projects like river maintenance that could affect local communities and nature. These reports help everyone understand the environmental effects before work begins, with public review periods ending soon. If you care about clean air and safe habitats, now’s the time to check out the details and share your thoughts!
Next: 2026-08522, Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company
Some folks want to buy shares in banks or bank companies, and the Federal Reserve is checking their applications to keep things safe and fair. If you want to share your thoughts, you’ve got until May 18, 2026, to speak up! This process helps make sure big money moves in banking happen smoothly and openly.